Primary outcome
UC
Time to recovery was a median 15 (10–19) 95% confidence interval [CI], 15 (9–24) and 11 (10–19) days in the UC, anakinra and tocilizumab groups, respectively. The differences between UC vs anakinra and UC vs tocilizumab were not statistically significant. Rate ratio for recovery for UC vs anakinra was 0.91 95% confidence interval [CI], 0.47 to 1.78, p = 0.8 and for UC vs tocilizumab 1.13; 95% [CI], 0.55 to 2.30; p = 0.7, 